Processing...
All Trials
Search
Search
There are 1652 active trials in our database.
Click on a trial to see more information.
1652 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Adults with metastatic/advanced NSCLC, gastroesophageal, colorectal, hepatocellular, pancreatic, or head and neck squamous cell carcinoma that has progressed on or is intolerant to standard systemic therapy (ECOG 0–2; measurable disease) receive DM005 (YH013) monotherapy IV Q3W. DM005 is a first-in-human bispecific antibody–drug conjugate targeting EGFR and c-MET, intended to preferentially bind EGFR/MET co-expressing tumors to enhance internalization and cytotoxic payload delivery, with dose escalation/expansion to define safety/MTD and assess preliminary activity.
ClinicalTrials.gov ID: NCT06515990
TrialFetch AI summary: Adults with advanced unresectable/metastatic/recurrent dMMR/MSI-H solid tumors (ECOG 0–2) who have exhausted standard options, with expansion limited to measurable colorectal or endometrial cancer after 1–3 prior systemic lines including at least one immune checkpoint inhibitor. Treatment is oral GSK5460025 monotherapy, a first-in-human nucleotide excision repair–dependent DNA-damaging agent being developed for dMMR/MSI-H tumors.
ClinicalTrials.gov ID: NCT07213609
TrialFetch AI summary: Enrolling adults with ECOG 0–1 and advanced CD70-expressing malignancies needing additional therapy: ccRCC after ≥1 prior line including ICI+TKI, DLBCL/high-grade B-cell lymphoma after ≥2 prior lines including immunochemotherapy and salvage, peripheral T-cell lymphoma after ≥1 systemic therapy, or CTCL (mycosis fungoides/Sézary) stage IIB+ with B0/B1 blood involvement after ≥1 systemic therapy. Participants receive INCA036873 monotherapy, an investigational CD70×CD3 bispecific T-cell engager intended to redirect T cells to kill CD70-positive tumor cells.
ClinicalTrials.gov ID: NCT07195916
TrialFetch AI summary: Eligible patients are children, adolescents, and young adults (age 1 to <24 years; >10 kg) with relapsed/refractory rhabdomyosarcoma, Ewing sarcoma, neuroblastoma, or Wilms tumor with measurable/evaluable disease after standard therapies and no known CNS involvement. After fludarabine/cyclophosphamide lymphodepletion, participants receive a single infusion of an autologous 1:1 cellular product combining B7-H3–targeted CAR T cells with PRAME antigen–specific T cells engineered with a dominant-negative TGF-β receptor II (dTβRII) to resist TGF-β–mediated immunosuppression.
ClinicalTrials.gov ID: NCT07172958
TrialFetch AI summary: For patients <30 years with unresectable, relapsed/refractory solid tumors requiring accessible biopsy (Part 2 enriched for fibrolamellar carcinoma; also HCC, DSRCT, and non-CNS malignant rhabdoid tumor), this single-arm study evaluates a 21-day regimen of metronomic oral cyclophosphamide plus PK-guided oral sorafenib (multikinase inhibitor of RAF/VEGFR/PDGFR) with IV bevacizumab (anti–VEGF-A) and IV atezolizumab (anti–PD-L1 checkpoint inhibitor) every 21 days. The trial focuses on safety/RP2D and preliminary response with sorafenib exposure targeting to reduce variability/toxicity.
ClinicalTrials.gov ID: NCT05468359
TrialFetch AI summary: Adults with unresectable or metastatic melanoma that has progressed after at least one prior systemic therapy including anti–PD-1 (ECOG 0–1; treated/stable brain metastases allowed) receive DOC1021 (dubodencel), a personalized autologous dendritic-cell vaccine made from mobilized peripheral blood cells and loaded with patient-specific tumor antigens (tumor lysate + amplified tumor mRNA) to induce Th1/cytotoxic T-cell responses, with peginterferon alfa-2a as an immune adjuvant. Treatment includes filgrastim mobilization with leukapheresis, two image-guided perinodal DOC1021 injections 2 weeks apart with 4 weeks of weekly peginterferon (optional 6‑month booster with additional peginterferon), and anti–PD-1 is held until ~6 weeks after the first DOC1021 dose (may be resumed later per protocol).
ClinicalTrials.gov ID: NCT07288112
TrialFetch AI summary: Eligible patients are adult women with recurrent/progressive advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer (non-carcinosarcoma) after ≥1 platinum regimen, appropriate for next-line single-agent therapy, ECOG 0–2, and with at least two measurable/detectable disease sites including a lesion amenable to biopsy to provide ~1 g tumor for vaccine manufacture. Participants receive an individualized inactivated autologous whole-tumor-cell vaccine (Innocell) designed to present patient-specific tumor antigens, given intradermally with CpG 1018 (TLR9 agonist adjuvant) every 2 weeks for 3 doses.
ClinicalTrials.gov ID: NCT06366490
TrialFetch AI summary: Enrolling adult women with measurable, advanced high-grade serous or endometrioid ovarian/fallopian tube/primary peritoneal carcinoma that is platinum-resistant or platinum-refractory (ECOG 0–1, adequate organ function). Participants receive intraperitoneal THEO-260, an investigational oncolytic adenovirus that selectively replicates in tumor tissue to cause tumor cell lysis and immune activation, administered as 6 doses over ~2 weeks in sequential dose-escalation cohorts.
ClinicalTrials.gov ID: NCT07211659
TrialFetch AI summary: Adults (≥18) with locally advanced or metastatic solid tumors harboring confirmed TP53 Y220C mutation, ECOG 0–1, with measurable disease and progression after ≥1 prior systemic therapy (excluding active CNS disease and significant cardiac/QT issues). Patients receive oral JAB-30355 monotherapy, a small-molecule mutant p53 (Y220C) reactivator that binds/stabilizes p53 toward a wild-type–like conformation to restore p53 transcriptional activity.
ClinicalTrials.gov ID: NCT06386146
TrialFetch AI summary: Eligible patients are men with metastatic castration-resistant prostate adenocarcinoma (ECOG 0–1, PSA ≥2 ng/mL) with progression on androgen-deprivation therapy and at least one prior approved secondary hormonal therapy for CRPC, without prior/active brain metastases or significant cardiac disease. Participants receive BMS-986460 monotherapy, an investigational ligand-directed degrader that binds a prostate tumor-associated antigen and recruits an E3 ubiquitin ligase to promote ubiquitination and proteasome-mediated degradation of a target protein in tumor cells.
ClinicalTrials.gov ID: NCT06067841